Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

296 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Among authors: do dv. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Pauleikhoff D, Bonelli R, Dubis AM, Gunnemann F, Rothaus K, Charbel Issa P, Heeren TF, Peto T, Clemons TE, Chew EY, Bird AC, Sallo FB; MacTel Study Group. Pauleikhoff D, et al. Acta Ophthalmol. 2019 Nov;97(7):e998-e1005. doi: 10.1111/aos.14110. Epub 2019 Apr 9. Acta Ophthalmol. 2019. PMID: 30968592 Free PMC article.
FeBr3-catalysed synthesis of 3-aroylimidazo[1,2-a]pyridine and 3,3'-(arylmethylene)bis(2-phenylimidazo[1,2-a]pyridines) derivatives from 2-arylimidazo[1,2-a]pyridines and aromatic aldehydes: an investigation about mechanistic insights.
Hung TQ, Phuc BV, Nguyen MP, Tran TL, Do DV, Nguyen HT, Nguyen VT, Nguyen H, Dang TT. Hung TQ, et al. Among authors: do dv. RSC Adv. 2024 Sep 18;14(40):29535-29541. doi: 10.1039/d4ra05198j. eCollection 2024 Sep 12. RSC Adv. 2024. PMID: 39297035 Free PMC article.
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).
Sharma A, Kaiser PK, Tadayoni R, Holz FG, Nicholson L, Vazquez-Alfageme C, Sivaprasad S, Wakabayashi T, Woo SJ, Sarraf D, Kumar N, Parachuri N, Regillo CD, Rezaei KA, Khanani AM, Bandello F, Shanamugam M, Verma L, Dogra MR, Ns M, Agarwal M, Loewenstein A, Kuppermann BD; International Retina Biosimilar Study Group (Inter BIOS Group). Sharma A, et al. Eye (Lond). 2024 Aug 26. doi: 10.1038/s41433-024-03284-x. Online ahead of print. Eye (Lond). 2024. PMID: 39187656 No abstract available.
Reply.
Matsumiya W, Karaca I, Pham BH, Akhavanrezayat A, Uludag G, Yasar C, Ghoraba H, Mobasserian A, Regenold J, Halim MS, Sepah YJ, Do DV, Chong V, Nguyen QD. Matsumiya W, et al. Among authors: do dv. Retina. 2024 Aug 1;44(8):e53-e55. doi: 10.1097/IAE.0000000000004134. Retina. 2024. PMID: 39047135
Biosimilar ranibizumab (BS1) - early experience from Japan (BRIJ study).
Ueda-Consolvo T, Ishida M, Nakamura T, Yanagisawa S, Tsuboi K, Wakabayashi T, Hayashi A, Sharma A; International Retina Biosimilar Study Group (Inter BIOS Group). Ueda-Consolvo T, et al. Eye (Lond). 2024 Jul 23. doi: 10.1038/s41433-024-03220-z. Online ahead of print. Eye (Lond). 2024. PMID: 39043816 No abstract available.
296 results